Ontology highlight
ABSTRACT:
SUBMITTER: Mahmoudpour SH
PROVIDER: S-EPMC6509335 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature
Mahmoudpour Seyed Hamidreza SH Jankowski Marius M Valerio Luca L Becker Christian C Espinola-Klein Christine C Konstantinides Stavros S Quitzau Kurt K Barco Stefano S
Scientific reports 20190509 1
Standard-dose intravenous recombinant interleukin-2 (rIL-2) is indicated for the treatment of some subtypes of cancer; however, severe adverse events, including venous thromboembolism (VTE), may complicate its administration. Low-dose subcutaneous rIL-2 is being studied for the management of immune-mediated diseases, since it can modulate the immunological response by specifically targeting T regulatory (T<sub>reg</sub>) cells; importantly, it is supposed to cause fewer or no complications. In t ...[more]